[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Silva RG, Dahmoush L, Gerke H: Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. JOP; 2006;7(1):66-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy.
  • CONTEXT: Malignant mixed Mullerian tumors are rare ovarian neoplasms that account for less than 2% of ovarian malignancies.
  • To our knowledge, this is the first report of a malignant mixed Mullerian tumor with metastasis to the pancreas.
  • The metastatic tumor was identified by endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and Trucut needle biopsy of the pancreas.
  • CASE REPORT: We describe a 69-year-old female with concomitant Duke's C adenocarcinoma of the colon and stage III-C malignant mixed Mullerian tumor that presented with malignant ascites, increasing abdominal girth and a pancreatic head mass.
  • EUS revealed an 11 cm cystic mass in the head of the pancreas that was characterized as a carcinosarcoma/malignant mesodermal mixed tumor by EUS-FNA and Trucut needle biopsy.
  • The patient was treated with palliative chemotherapy and a three-month follow up CT scan did not reveal any new metastatic lesions.
  • CONCLUSION: The pancreas is a rare site of metastasis and more commonly seen in renal cell carcinoma, melanoma or lung tumors; amongst others.
  • Although ovarian adenocarcinoma has been reported as a primary site of pancreatic metastasis, it has not been previously described originating from a mixed Mullerian tumor of the ovary presenting as a cystic pancreatic head mass.
  • [MeSH-major] Mixed Tumor, Mullerian / secondary. Ovarian Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle / methods. Endosonography. Female. Humans. Neoplasm Staging. Pancreas / pathology. Pancreas / radiography. Prognosis. Tomography, X-Ray Computed


2. Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, Tafesse E, Menzin J: Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg; 2009 Jun;135(6):582-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.
  • OBJECTIVE: To evaluate the incidence and costs of complications due to radiotherapy alone vs platinum-based chemoradiotherapy among patients diagnosed as having advanced squamous cell carcinoma of the head and neck (ASCCHN) from a payer perspective.
  • PATIENTS: The study included patients with ASCCHN and an indication of a secondary malignant neoplasm (both identified based on International Classification of Diseases, Ninth Revision, Clinical Modification, diagnosis codes), 124 of whom were treated with radiotherapy alone and 77 of whom were treated with chemoradiotherapy (including 53 with cisplatin plus radiotherapy, 26 with carboplatin plus radiotherapy, and 2 with cisplatin and carboplatin plus radiotherapy).
  • The patients were assigned to 1 of 2 cohorts based on treatment type-radiotherapy only and platinum-based chemoradiotherapy-and were followed up for 6 months.
  • MAIN OUTCOME MEASURES: Incidence and costs of treatment-related complications associated with chemotherapy in ASCCHN.
  • RESULTS: We found significantly (P < .001) higher rates of treatment-related complications among patients receiving chemoradiotherapy (86%) than among patients receiving only radiotherapy (51%).
  • The mean per-patient costs associated with treatment-related complications were approximately $10 000 higher among patients who received chemoradiotherapy than among those treated with radiotherapy alone (P < .001).
  • CONCLUSIONS: Our study results suggest that the attributable incidence and costs of treatment-related complications associated with chemotherapy in ASCCHN are substantial.
  • The emergence of safer treatments may have the advantage of alleviating this cost burden.
  • [MeSH-major] Carcinoma, Squamous Cell / economics. Carcinoma, Squamous Cell / therapy. Cost of Illness. Head and Neck Neoplasms / economics. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Carboplatin / adverse effects. Cisplatin / adverse effects. Combined Modality Therapy. Databases, Factual. Drug Therapy / economics. Drug-Related Side Effects and Adverse Reactions. Female. Hospitalization. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / economics. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / economics. Pharyngeal Neoplasms / radiotherapy. Postoperative Complications / economics. Radiation-Sensitizing Agents / adverse effects. Radiotherapy / adverse effects. Radiotherapy / economics. Retrospective Studies. Tongue Neoplasms / drug therapy. Tongue Neoplasms / economics. Tongue Neoplasms / radiotherapy. United States

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19528407.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is an increased incidence of second malignant neoplasms in survivors of childhood cancers.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Although, ionizing radiation has been demonstrated to increase the risk of developing a salivary gland neoplasm, there are few reports of salivary gland neoplasms occurring in patients treated for cancer in childhood.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


Advertisement
4. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM: Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol; 2005 May 20;23(15):3495-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
  • PURPOSE: To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma.
  • PATIENTS AND METHODS: Thirty-three patients with malignant pleural mesothelioma and free-flowing pleural effusions received intrapleural L-NDDP once every 3 weeks at a dose of 450 mg/m2.
  • Thoracoscopic evaluation with pleural biopsies was performed before therapy and then after every two cycles.
  • RESULTS: After at least two cycles, post-treatment pleural biopsy analysis was negative in 14 patients for a pathologic response rate of 42% (95% CI, 25% to 61%).
  • There were three treatment-related deaths secondary to peritonitis, cellulitis at the thoracoscopy site, and empyema.
  • CONCLUSION: Intrapleural L-NDDP therapy in this patient population is feasible with significant but manageable toxicity.
  • Although pathologic responses are highly encouraging, areas of mesothelioma that are not in direct communication with the pleural space will evade drug exposure and limit efficacy in some patients.
  • The optimal role of intrapleural L-NDDP therapy currently remains to be determined.
  • [MeSH-major] Mesothelioma / drug therapy. Mesothelioma / pathology. Organoplatinum Compounds / administration & dosage. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Cancer, Regional Perfusion. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Carriers. Female. Follow-Up Studies. Humans. Immunohistochemistry. Liposomes. Male. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Survival Rate. Thoracoscopy. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908659.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-00167; United States / NCI NIH HHS / CA / K12 CA088084
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)
  •  go-up   go-down


5. el-Zeftawy H, Heiba SI, Jana S, Rosen G, Salem S, Santiago JF, Abdel-Dayem HM: Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm; 2001 Feb;16(1):37-46
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
  • AIM OF THE STUDY: To assess the impact of repeated F-18 FDG studies on the management of patients with bone and soft tissue (B&S) sarcomas.
  • MATERIAL AND METHODS: Twenty patients with B&S tissue tumors (11 M and 9 F age 17-72 years) had 52 F-18 FDG Dual Head Coincidence Imaging (DHCI) studies.
  • Patient's preparation, F-18 FDG injection and imaging procedure were done according to department protocol.
  • RESULTS: In 13 patients having both studies, baseline FDG and CT/MRI were concordant in 8 patients, FDG detected more lesions in 3 patients but it did not detect 4 metastatic pulmonary nodules in 2 patients.
  • Follow up studies showed stable disease in 10 patients while 6 patients who showed worsening disease needed to change their chemotherapy.
  • CONCLUSION: Repeated F-18 FDG DHCI examinations proved to have an impact on the clinical management of patients with malignant bone and soft tissue sarcoma.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / secondary. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Male. Middle Aged. Posture. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11279796.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Bien E, Stachowicz-Stencel T, Balcerska A, Godzinski J, Kazanowska B, Perek-Polnik M, Madziara W, Rybczynska A, Kurylak A, Zalewska-Szewczyk B, Peregud-Pogorzelski J: Angiosarcoma in children - still uncontrollable oncological problem. The report of the Polish Paediatric Rare Tumours Study. Eur J Cancer Care (Engl); 2009 Jul;18(4):411-20
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The report of the Polish Paediatric Rare Tumours StudyAngiosarcoma is a rare, highly malignant vascular neoplasm with little data available on its clinical course and management in children.
  • Ten children with angiosarcoma (M/F: 6/4; aged 2, 3-16 years) registered in Polish Paediatric Rare Tumours and Soft Tissue Sarcomas Studies between 1992 and 2006.
  • Primary tumour exceeded 5 cm in seven patients and affected mainly deep tissues (heart-2, head/neck, bladder, brain, liver and upper limb - one patient each).
  • Four patients had regional and two metastatic diseases (lungs and bones).
  • All patients received supplementing chemotherapy with no response in four.
  • Three of five secondary tumour resections proved complete.
  • Seven patients experienced relapses (mainly metastatic) and two continuous progression.
  • Relapsed patients received chemotherapy +/- radiotherapy and surgery (three).
  • Nine patients died of disease (overall survival 6-66 months), and one child after mutilating secondary resection is alive.
  • The response to chemotherapy is poor and the large number of metastatic recurrences suggests a need for systemic therapy modifications.
  • [MeSH-major] Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Humans. Male. Poland / epidemiology. Prognosis. Radiotherapy. Recurrence. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19490008.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Nishiura Y, Sakamoto K, Mihoki T, Takane Y, Maeda A, Miyajima Y, Nakashima T: [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Nov;109(11):781-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity].
  • Malignant melanoma usually occurs in tissues containing large numbers of melanocytes, such as the skin, mucosa and eye, and is one of the most highly malignant tumors known.
  • No satisfactory treatment results have ever been reported.
  • We report here an effective course of immunotherapy consisting of the local injection and intra-venous administration of autologous tumor-cell-stimulated cytotoxic T lymphocytes in a patient with recurrent malignant melanoma.
  • She had been diagnosed as having malignant melanoma in 1996 and under went radio-chemotherapy at our hospital.
  • Following systematic chemotherapy, 23 local injections of cytotoxic T lymphocytes were performed.
  • Immunotherapy using cytotoxic T lymphocytes may be a useful strategy for controlling recurrent malignant melanoma.
  • [MeSH-major] Immunotherapy / methods. Melanoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. T-Lymphocytes, Cytotoxic / transplantation
  • [MeSH-minor] Female. Humans. Interleukins / therapeutic use. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Middle Aged. Neoplasm Recurrence, Local. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165592.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukins
  •  go-up   go-down


8. Werner JA, Dünne AA: Value of neck dissection in patients with squamous cell carcinoma of unknown primary. Onkologie; 2001 Feb;24(1):16-20
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymph node metastases of cancer of an unknown primary (CUP syndrome) are responsible for 3-5% of the malignant diseases in the head and neck area.
  • For a curative approach modified radical neck dissection combined with postoperative radiation therapy with or without chemotherapy should be considered in N1-N3 lymph node status.
  • A radical neck dissection with postoperative radiation therapy should only be approved in cases of infiltration of the internal jugular vein, the accessory nerve and/or the sternocleidomastoid muscle.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Lymphatic Metastasis / pathology. Neck Dissection. Neoplasms, Unknown Primary / surgery
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger GmbH, Freiburg
  • (PMID = 11441275.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 37
  •  go-up   go-down


9. Zhi K, Ren W, Zhou H, Wen Y, Zhang Y: Management of parapharyngeal-space tumors. J Oral Maxillofac Surg; 2009 Jun;67(6):1239-44
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cases were evaluated with at least a computed tomography scan.
  • The most common class of lesion was salivary-gland neoplasm, accounting for 74 cases (45.68%).
  • Only 22 patients (13.58%) presented with malignant disease.
  • Twenty patients with malignant disease underwent adjuvant chemotherapy and/or radiotherapy.
  • Two patients suffered local failure, and 4 patients developed distant metastasis during the observation period.
  • CONCLUSIONS: Surgery is the mainstay treatment for PPS tumors.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Pharyngeal Neoplasms / surgery
  • [MeSH-minor] Adenoma, Pleomorphic / surgery. Adult. Biopsy, Fine-Needle. Carcinoma / secondary. Carcinoma / surgery. Chemotherapy, Adjuvant. Cranial Nerve Diseases / etiology. Female. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neck Muscles / surgery. Neoplasm Recurrence, Local / pathology. Parotid Gland / surgery. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Salivary Gland Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Oral Maxillofac Surg. 2010 May;68(5):1209-11; author reply 1212 [20403530.001]
  • (PMID = 19446210.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Five years after the patient presented with melena and acute anemia; during endoscopic examination, a large bleeding duodenal polyp was found, so a surgical resection of the gastric antrum, duodenum, head of the pancreas, main bile ducts and gallbladder was performed.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Paludetti G, Almadori G, Bussu F, Galli J, Cadoni G, Maurizi M: Hypofolatemia as a risk factor for head and neck cancer. Adv Otorhinolaryngol; 2005;62:12-24
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofolatemia as a risk factor for head and neck cancer.
  • Head and neck cancer (HNSCC) includes squamous cell carcinomas of the oral cavity, pharynx and larynx.
  • HNSCCs represent about 3% of all malignant tumors in the USA.
  • The standard therapeutic approach, focused on surgery, irradiation and chemotherapy, alone or in combination, has been in part modified in the last 30 years, but the overall survival of HNSCC patients has not substantially improved.
  • To characterize and thus identify high-risk mucosal areas and preclinical tumors, molecular abnormalities in head and neck carcinogenesis have been extensively studied.
  • Metabolic aspects in head and neck carcinogenesis have been less extensively studied.
  • These may be secondary or may precede tumor development and favorite progression.
  • In particular, based upon our results, a role for folate deficiency as a risk factor in head and neck carcinogenesis seems plausible.
  • An accumulation of homocysteine might reveal a genetic defect which is theoretically a target for pharmacological therapy, for example by antifolic drugs.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Glutamate Carboxypeptidase II / blood. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / pathology. Homocysteine / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy, Needle. Case-Control Studies. Cohort Studies. Female. Humans. Immunohistochemistry. Italy / epidemiology. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Male. Middle Aged. Mouth Neoplasms / epidemiology. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Neoplasm Staging. Prognosis. Reference Values. Risk Factors. Sensitivity and Specificity. Smoking / adverse effects. Smoking / epidemiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15608414.001).
  • [ISSN] 0065-3071
  • [Journal-full-title] Advances in oto-rhino-laryngology
  • [ISO-abbreviation] Adv. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0LVT1QZ0BA / Homocysteine; EC 3.4.17.21 / Glutamate Carboxypeptidase II
  •  go-up   go-down


12. Rigual NR, Popat SR, Jayaprakash V, Jaggernauth W, Wong M: Cutaneous head and neck melanoma: the old and the new. Expert Rev Anticancer Ther; 2008 Mar;8(3):403-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous head and neck melanoma: the old and the new.
  • The incidence rate of malignant melanoma has shown a rapid worldwide rise in recent years.
  • The staging and management of head and neck melanoma presents some unique challenges.
  • Surgery remains the cornerstone of treatment, while sentinel node biopsy is the most accurate staging modality for regional disease.
  • The complex regional anatomy and lymphovascular drainage of this region may account for the increased biologic aggressiveness and treatment challenges of this disease.
  • The treatment outcomes of metastatic head and neck melanoma remain disappointing but important progress has been made in the understanding of melanoma biology.
  • [MeSH-major] Head and Neck Neoplasms. Melanoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / radiotherapy. Hutchinson's Melanotic Freckle / secondary. Hutchinson's Melanotic Freckle / surgery. Immunotherapy. Interferons / therapeutic use. Interleukin-2 / administration & dosage. Interleukin-2 / therapeutic use. Lymphatic Metastasis. Neoplasm Staging. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366288.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 9008-11-1 / Interferons
  • [Number-of-references] 85
  •  go-up   go-down


13. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • RESULTS: The 5-year actuarial local control rate for stage I (limited to the site of origin; 22 patients) was 86%; for stage II (extension to adjacent sites (eg, adjacent sinuses, orbit, pterygomaxillary fossa, nasopharynx; 21 patients) was 65%; and for stage III (destruction of skull base or pterygoid plates, or intracranial extension; 35 patients) was 34%.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • Twenty-one (27%) of 78 patients had unilateral blindness develop secondary to radiation retinopathy or optic neuropathy; the complication was anticipated in most of these patients, because the ipsilateral eye was irradiated to a high dose.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • Second neoplasm developed in 32 cases (4.8%).
  • Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia.
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Song Y, He J, Wu LY, Wang LH, Wang JW: [Treatment and prognosis of extrapulmonary small cell carcinoma of 243 cases]. Zhonghua Zhong Liu Za Zhi; 2010 Feb;32(2):132-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of extrapulmonary small cell carcinoma of 243 cases].
  • OBJECTIVE: The extrapulmonary small cell carcinoma (EPSCC), a uncommon malignant tumor, has seldom been reported.
  • The aim of this study was to analyze the clinical characteristics, treatment and prognosis of EPSCC.
  • 170 patients received chemotherapy-based multimodal therapy, 73 received surgery, and/or radiotherapy.
  • Among different primary sites, patients with gynecologic small cell cancer had a median survival of 28.0 months, head and neck 20.1 months and gastrointestinal tract 14.3 months.
  • CONCLUSION: EPSCC is an uncommon malignant tumor with early metastasis and poor prognosis.
  • These differences may influence the choice of therapeutic strategy.
  • Multimodal therapy, combination of chemo- and radio-therapy after surgical resection may improve the outcome of EPSCC.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Esophageal Neoplasms / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Etoposide / therapeutic use. Female. Follow-Up Studies. Gastrointestinal Neoplasms / pathology. Gastrointestinal Neoplasms / surgery. Gastrointestinal Neoplasms / therapy. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiotherapy, High-Energy. Survival Rate. Urogenital Neoplasms / pathology. Urogenital Neoplasms / surgery. Urogenital Neoplasms / therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403245.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VP-P protocol
  •  go-up   go-down


16. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature.
  • The thyroid gland is a relatively uncommon site for a secondary malignancy; even less common is a case of malignant melanoma metastatic to the thyroid.
  • Fine-needle aspiration biopsy (FNAB) identified the mass as a malignant melanoma.
  • Postoperatively, he declined to undergo radio- and chemotherapy.
  • FNAB again attributed the enlargement to malignant melanoma.
  • Soon thereafter, the patient began experiencing seizures, and on magnetic resonance imaging, he was found to have metastatic disease to the brain.
  • He developed ventilator-dependent respiratory failure and required a subtotal thyroidectomy for the placement of a tracheostomy tube.
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


17. Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnait F, Rappersberger K, Pilarski P, Pehamberger H, European Cooperative Adjuvant Melanoma Treatment Study Group: Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. J Clin Oncol; 2005 Dec 1;23(34):8655-63
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
  • PURPOSE: The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines, but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma.
  • We evaluated safety and efficacy of IFNalpha and isotretinoin compared with IFNalpha alone as adjuvant treatment in patients with primary malignant melanoma stage IIA and IIB.
  • IFNalpha was administered three times a week at a dose of 3 million units subcutaneously for 24 months.
  • CONCLUSION: The addition of isotretinoin to an adjuvant treatment of low-dose IFNalpha in patients with stage IIA and IIB melanoma had no significant effect on disease-free or overall survival and is therefore not recommended.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Isotretinoin / therapeutic use. Melanoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Chemotherapy, Adjuvant. Disease-Free Survival. Double-Blind Method. Europe. Female. Humans. Hyperlipidemias / chemically induced. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Prospective Studies. Quality of Life. Skin Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Dec 1;23(34):8559-63 [16260699.001]
  • (PMID = 16260701.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; EH28UP18IF / Isotretinoin
  •  go-up   go-down


18. Vargas H, Mouzakes J, Purdy SS, Cohn AS, Parnes SM: Follicular dendritic cell tumor: an aggressive head and neck tumor. Am J Otolaryngol; 2002 Mar-Apr;23(2):93-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular dendritic cell tumor: an aggressive head and neck tumor.
  • OBJECTIVE: To characterize the clinicopathologic features of head and neck follicular dendritic cell (FDC) tumor and report the experience of this entity at our institution.
  • STUDY DESIGN: Two case presentations are compared with a retrospective analysis of all published head and neck cases.
  • RESULTS: Thirty four cases of FDC tumor of the head and neck cases have been published.
  • Patients were treated with surgery (17), surgery and chemotherapy (8), and surgery and radiation (9).
  • After the primary treatment, 12 patients had no evidence of disease, whereas 5 were incurable.
  • Of these 13 patients who suffered recurrences, 4 had no evidence of disease after secondary treatment, 6 were alive with disease, and one was lost to follow up.
  • CONCLUSION: FDC tumor is a rare malignant neoplasm that can present in the head and neck region in both lymph nodes and extranodal sites.
  • Surgery has been the mainstay of treatment and should include diligent control of surgical margins.
  • The role of adjuvant therapy remains controversial.
  • Although originally considered to be a low-grade malignancy, our review suggests both high recurrence rates and metastatic potential.
  • We believe that FDC tumor should be viewed and treated as a moderately aggressive head and neck tumor.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Parotid Neoplasms / diagnosis. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery. Severity of Illness Index. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Dendritic Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.)
  • (PMID = 11893977.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


19. Savoia P, Fierro MT, Zaccagna A, Bernengo MG: Metastatic melanoma of the heart. J Surg Oncol; 2000 Nov;75(3):203-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma of the heart.
  • BACKGROUND: Malignant melanoma has an unpredictable biologic behavior and is the neoplasm with the greatest propensity for cardiac involvement.
  • METHODS: We reviewed 2,810 patients with histologically confirmed malignant melanoma, who were diagnosed and followed up by our clinic.
  • RESULTS: Five cases of metastatic melanoma of the heart were identified out of 314 melanoma patients with visceral involvement.
  • One case of a 53-year-old woman, who died unexpectedly during her first chemotherapy course, is described in detail.
  • CONCLUSIONS: The unpredictable biologic behavior of melanoma may lead to unusual metastatic sites, and, therefore, the heart also should be included in routine examinations.
  • [MeSH-major] Heart Neoplasms / pathology. Heart Neoplasms / secondary. Melanoma / pathology. Melanoma / secondary
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Male. Middle Aged. Thoracic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11088053.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Takeyama H, Takahashi H, Tabei I, Fukuchi O, Nogi H, Kinoshita S, Uchida K, Morikawa T: Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland. Breast Cancer; 2010 Apr;17(2):151-4
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasm in the axilla of a male: suspected primary carcinoma of an accessory mammary gland.
  • Incisional biopsy for suspected malignancy was performed, and histopathologic examination by hematoxylin-eosin (H&E) staining yielded a diagnosis of poorly differentiated adenocarcinoma metastatic from an unknown primary.
  • As the tumor was immunohistochemically positive for both ER and PgR, metastatic breast cancer was strongly suspected.
  • Detailed examination of the head and neck region, lung, and upper and lower gastrointestinal tract also revealed no evidence of a primary tumor.
  • After chemotherapy, the patient underwent tumor resection with axillary lymph node dissection.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms, Male / pathology. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Axilla. Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387775.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Markowski J, Gierek T, Zielińska-Pajak E, Witkowska M, Wodołazski A, Pajak J, Paluch J: [Distant metastases to the parotid gland--review of the literature and report of own two cases]. Otolaryngol Pol; 2005;59(4):547-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic tumors to the parotid gland are very uncommon and it accounts for 8% of all cancers of parotid gland.
  • The parotid gland and its lymph nodes are possible sites of metastases from head and neck cancers.
  • However, metastasis from distant primary neoplasm below clavicle is possible, too.
  • The women with breast cancer and metastases to the parotid gland 11 years after surgery, radio- and chemotherapy of breast cancer.
  • The man with metastasis of malignant melanoma of unknown primary site.
  • The authors described pathophysiology of distant metastases to the parotid gland with special attention to possibilities of treatment and survival.
  • [MeSH-major] Breast Neoplasms / pathology. Melanoma / pathology. Neoplasms, Unknown Primary / genetics. Neoplasms, Unknown Primary / pathology. Parotid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273860.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 15
  •  go-up   go-down


22. Woźniak AW, Nowaczyk MT, Osmola K, Golusinski W: Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature. Eur Arch Otorhinolaryngol; 2010 Jun;267(6):845-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature.
  • The histopathological diagnosis was one of osteoblastoma.
  • Postoperative recurrence with soft tissue infiltration suggested an osteosarcoma radiologically, but the histological examination again revealed the presence of an osteoblastoma.
  • A second recurrence occured in the pharyngo-glossal region and this time the tumor was histologically diagnosed as an osteoblastoma, but with foci of well-differentiated osteosarcoma.
  • The patient was given a course of radiotherapy, but clinical and radiological examination 8 months later revealed lung metastases and chemotherapy was started.
  • While osteoblastomas are rare, and their sarcomatous change even rarer, our experience with this case lead us to suggest that a therapeutic preventative approach, involving both chemotherapy and total excision of the tumor, is the regime to adopt with osteoblastomas which involve soft tissues and have radiological features suggesting malignancy.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteoblastoma / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Mandible / pathology. Mandible / surgery. Radiography, Panoramic. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Spine J. 1998;7(3):246-8 [9684960.001]
  • [Cites] J Clin Pathol. 1993 Nov;46(11):1024-9 [8254089.001]
  • [Cites] Neurosurg Rev. 1997;20(1):51-4 [9085288.001]
  • [Cites] Histopathology. 1997 Aug;31(2):196-200 [9279574.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):305-9 [9078333.001]
  • [Cites] Skeletal Radiol. 1994 Oct;23 (7):509-12 [7824976.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):138-42 [2045899.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):377-92 [8780939.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 1:S91-7 [9652508.001]
  • [Cites] Skeletal Radiol. 1994 Nov;23 (8):656-9 [7886478.001]
  • [Cites] Aktuelle Radiol. 1996 Nov;6(6):338-40 [9081408.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):416-26 [3855268.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):116-8 [8576460.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):117-34 [8119712.001]
  • [Cites] Chirurg. 2002 Dec;73(12 ):1181-90 [12491047.001]
  • [Cites] Arq Neuropsiquiatr. 1998 Jun;56(2):292-5 [9698743.001]
  • [Cites] J Laryngol Otol. 1997 Sep;111(9):865-8 [9373556.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jan;52(1):86-90 [8263651.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Feb;18(2):324-6 [9111670.001]
  • [Cites] Surg Neurol. 1998 Mar;49(3):274-7 [9508114.001]
  • (PMID = 20012077.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


23. Thompson LD, Wieneke JA, Miettinen M: Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol; 2003 May;27(5):594-611
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sinonasal tract mucosal malignant melanomas are uncommon tumors that are frequently misclassified, resulting in inappropriate clinical management.
  • A total of 115 cases of sinonasal tract mucosal malignant melanoma included 59 females and 56 males, 13-93 years of age (mean 64.3 years).
  • Histologically, the tumors were composed of a variety of cell types (epithelioid, spindled, undifferentiated), frequently arranged in a peritheliomatous distribution (n = 39).
  • Immunohistochemical studies confirmed the diagnosis of sinonasal tract mucosal malignant melanomas with positive reactions for S-100 protein, tyrosinase, HMB-45, melan A, and microphthalmia transcription factor.
  • Sinonasal tract mucosal malignant melanomas need to be considered in the differential diagnosis of most sinonasal malignancies, particularly carcinoma, lymphoma, sarcoma, and olfactory neuroblastoma.
  • Surgery accompanied by radiation and/or chemotherapy was generally used.
  • The majority of patients developed a recurrence (n = 79), with 75 patients dying with disseminated disease (mean 2.3 years), whereas 40 patients are either alive or had died of unrelated causes (mean 13.9 years).
  • A TNM-type classification separated by anatomic site of involvement and metastatic disease is proposed to predict biologic behavior.
  • [MeSH-major] Melanoma / secondary. Nasopharyngeal Neoplasms / pathology. Nose Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Mucosa. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717245.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Mosca F, Stracqualursi A, Lipari G, Persi A, Latteri S: [Malignant stromal tumors of the duodenum. Report of a case]. Chir Ital; 2000 Nov-Dec;52(6):725-32
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant stromal tumors of the duodenum. Report of a case].
  • The Authors report a rare case of undifferentiated duodenal malignant stromal tumour in a 69-years-old man radically managed by pancreaticoduodenectomy and resection of a liver metastasis.
  • Several preoperative tests were performed (barium meal, endoscopy, ultrasonography and CT scan) but failed to yield a differential diagnosis between a tumour of the pancreatic head and a retroperitoneal neoplasm.
  • The diagnosis was only histological.
  • Thorough surveillance revealed several hepatic metastases 29 months after resection, and chemotherapy performed at this stage proved completely ineffective.
  • [MeSH-major] Duodenal Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / secondary. Male. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200011.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Zhang WC, Cheng JP, Li Q, Zhang L, Wang XD, Anniko M: Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases. Acta Otolaryngol; 2009 Nov;129(11):1320-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological analysis of malignant carotid body tumour: a report of nine cases.
  • CONCLUSIONS: Malignant carotid body tumour (MCBT) is a clinically rare disease that often invades the carotid artery and cranial nerves.
  • Diagnosis of malignant tumour should be based on extensive invasion of neighbouring organs and distant metastasis.
  • Radiotherapy is effective, whereas chemotherapy is uncertain.
  • OBJECTIVE: To summarize the clinical pathological and prognostic characteristics of MCBT and explore methods for diagnosis and treatment.
  • MATERIALS AND METHODS: The study material comprised clinical, pathological, therapeutic and follow-up data concerning nine patients (four males, five females) with MCBT, treated at Tianjin Cancer Hospital between January 1956 and June 2006.
  • Shamblin classification was: one case, type II; 8 cases, type III.
  • The histopathological diagnosis in all nine cases was MCBT.
  • [MeSH-minor] Adult. Carotid Arteries / pathology. Carotid Arteries / surgery. Combined Modality Therapy. Cranial Nerves / pathology. Disease Progression. Disease-Free Survival. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Postoperative Complications / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863331.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Gadwal SR, Fanburg-Smith JC, Gannon FH, Thompson LD: Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature. Cancer; 2000 May 1;88(9):2181-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chondrosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 14 cases with a review of the literature.
  • BACKGROUND: Primary chondrosarcoma of the head and neck in the pediatric age group is rare.
  • METHODS: Fourteen cases of chondrosarcoma of the head and neck from patients age 18 years or younger, diagnosed between 1970 and 1997, were retrieved from the Otorhinolaryngic-Head & Neck Tumor Registry of the Armed Forces Institute of Pathology.
  • No secondary sarcomas (radiation-induced or arising in association with Maffucci syndrome or Ollier disease) were included.
  • All tumors were invasive and malignant as determined by radiology and/or histology.
  • All patients were treated by surgery, followed by radiation (n=5) and/or chemotherapy (n=2).
  • CONCLUSIONS: Primary head and neck chondrosarcoma in the pediatric population is typically low grade and occurs in the maxillary sinus or mandible.
  • [MeSH-major] Chondrosarcoma / pathology. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Headache / diagnosis. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Nasal Obstruction / diagnosis. Neoplasm Invasiveness. Nose Neoplasms / pathology. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhinitis / diagnosis. Sinusitis / diagnosis

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813732.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


27. Konstadoulakis MM, Messaris E, Zografos G, Androulakis G, Karakousis C: Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? J Neurosurg Sci; 2000 Dec;44(4):211-8; discussion 219
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery?
  • BACKGROUND: The aim of this study is to evaluate the prognostic parameters and treatment modalities of malignant melanoma patients with brain metastases.
  • INTERVENTIONS: all patients were treated surgically and in the majority adjuvant therapy was applied.
  • MEASURES: survival and time of recurrence of patients and possible prognostic factors.
  • RESULTS: PATIENTS who were treated surgically had a better one-year survival rate (28.3%), than patients who received radiotherapy and/or chemotherapy (6.67%) or patients who refused any kind of treatment (3.45%), (p=0.006).
  • Prolonged survival after surgical treatment was found in patients with single metastatic lesions and in patients with multiple metastatic lesions.
  • CONCLUSIONS: Melanoma patients with single metastatic lesions to the brain seem to do better after surgical treatment.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Melanoma / secondary. Melanoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / secondary. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11327290.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement